LINGO-1 inhibitors(Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitors), Cell differentiation stimulants

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEye Diseases+ [1]

Active Indication-

Inactive Indication

Multiple sclerosis relapseMultiple Sclerosis, Relapsing-RemittingOptic Neuritis

Originator Organization

Biogen, Inc.

Dyax Corp.

Active Organization-

Inactive Organization

Biogen, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 1311317H

Source: *****

Sequence Code 9535515L

Source: *****

Clinical Trials associated with Opicinumab

NCT03222973

/ TerminatedPhase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS.
The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.

Start Date15 Nov 2017

Sponsor / Collaborator

Biogen, Inc.

NCT02833142

/ CompletedPhase 1

A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers

The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers. Secondary objectives are: To assess the safety and tolerability of BIIB033-A and BIIB033-B; To assess the secondary PK parameters of BIIB033-A and BIIB033-B; To assess the immunogenicity of BIIB033-A and BIIB033-B.

Start Date01 Jul 2016

Sponsor / Collaborator

Biogen, Inc.

NCT02657915

/ CompletedPhase 2

A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201

The primary objective of the study is to assess full-field visual evoked potential (FF-VEP) latency in subjects who were enrolled in Study NCT01721161 2 years (+ up to 12 months) after the last study visit. The secondary objective is to assess clinical progression and severity of central nervous system (CNS) demyelinating disease in subjects who were enrolled in Study NCT01721161 2 years (+ up to 12 months) after the last study visit. Intervention was administered in the previous study. The participants, investigator and outcome assessors remain blinded in this follow-up study.

Start Date10 Mar 2016

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Opicinumab

100 Translational Medicine associated with Opicinumab

100 Patents (Medical) associated with Opicinumab

Literatures (Medical) associated with Opicinumab

01 Jan 2025·Multiple Sclerosis and Related Disorders

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Article

Author: Cheng, Wenting ; Bradley, Daniel P ; Zhu, Bing ; Ziemssen, Focke ; Butzkueven, Helmut ; Leocani, Letizia ; Belachew, Shibeshih ; Balcer, Laura J ; Naylor, Maria L ; Klistorner, Alexander ; Galetta, Steven L ; Ziemssen, Tjalf ; Aktas, Orhan ; Franchimont, Nathalie ; Izquierdo, Guillermo ; Castrillo-Viguera, Carmen

BACKGROUND:

The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the latency recovery of visual evoked potential (VEP) were observed between opicinumab and placebo groups in the intention to treat (ITT) population, the prespecified per-protocol (PP) population showed better recovery with opicinumab than with placebo. RENEWED (NCT02657915) was a one-visit, follow-up study 2 years after the last RENEW study visit (Week 32) designed to assess the long-term electrophysiological and clinical outcomes for participants previously enrolled and having received study treatment in RENEW.

METHODS:

In the original study (RENEW), participants (aged 18-55 years) with a first unilateral AON episode were enrolled ≤28 days from first symptom onset and after treatment with methylprednisolone 1 g/day intravenously for 3-5 days; these participants were randomized to receive opicinumab 100 mg/kg or placebo intravenously once every 4 weeks from baseline to Week 20, assessed up to Week 32. Participants who received ≥1 dose of opicinumab 100 mg/kg or placebo in RENEW were eligible for the RENEWED follow-up study. Participants enrolled in RENEWED at 2 years (with an additional up to 12-month window) after the last RENEW study visit (Week 32) in both ITT and PP populations. The primary endpoint was change in full-field VEP (FF-VEP) latency of the affected eye at RENEWED study visit versus baseline of the fellow eye in RENEW, comparing between participants who received opicinumab and placebo in RENEW. Clinical progression and severity of multiple sclerosis (MS) were assessed. A substudy evaluated latency recovery using multifocal VEP (mfVEP) as an exploratory endpoint.

RESULTS:

Of 82 RENEW participants, 52 (63.4 %; opicinumab n = 28, placebo n = 24) enrolled in and completed RENEWED. The adjusted mean (95 % CI) difference in FF-VEP latency delay between opicinumab and placebo groups was -6.0 (-14.6, 2.6) msec (p = 0.165) for the PP population and -4.5 (-12.6, 3.7) msec (p = 0.274) for the ITT population at the RENEWED study visit. Nominally significant improvement on mfVEP latency in the opicinumab group versus placebo was observed in participants of the mfVEP substudy (p = 0.009). In participants from the PP population without clinically definite MS (CDMS) at RENEW baseline,12 (55 %) in the opicinumab group and 12 (67 %) in the placebo group developed CDMS from enrollment in the RENEW study up to RENEWED Day 1; the estimated proportion of participants with CDMS at 2 years after the last study visit assessment in RENEW was lower when treated with opicinumab (0.50) than when treated with placebo (0.61) (hazard ratio p-value = 0.23). No benefit on visual acuity or other neurological functions was observed in the opicinumab group vs placebo in RENEWED.

CONCLUSION:

The numerically increased VEP latency recovery with opicinumab treatment in RENEWED was consistent with those observed in the parent study RENEW. However, the VEP latency and clinical data in RENEWED should be interpreted with caution, given the nature of the follow-up study, the small sample size and the limitation in study design.

01 Jul 2024·Current neuropharmacology

Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Review

Author: Bonaventura, Gabriele ; Cantarella, Giuseppina ; Di Mauro, Rosaria ; Di Benedetto, Giulia ; Cantone, Anna Flavia ; Mariottini, Alice ; La Cognata, Valentina ; Bellanca, Carlo Maria ; Augello, Egle ; Massacesi, Luca ; Attaguile, Giuseppe ; Bernardini, Renato

Abstract::

Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades, remarkable results have been achieved in the treatment of MS, particularly in the relapsing- remitting (RRMS) form, thus improving the long-term outcome for many patients. As deeper knowledge of MS pathogenesis and respective molecular targets keeps growing, nowadays, several lines of disease-modifying treatments (DMT) are available, an impressive change compared to the relative poverty of options available in the past. Current MS management by DMTs is aimed at reducing relapse frequency, ameliorating symptoms, and preventing clinical disability and progression. Notwithstanding the relevant increase in pharmacological options for the management of RRMS, research is now increasingly pointing to identify new molecules with high efficacy, particularly in progressive forms. Hence, future efforts should be concentrated on achieving a more extensive, if not exhaustive, understanding of the pathogenetic mechanisms underlying this phase of the disease in order to characterize novel molecules for therapeutic intervention. The purpose of this review is to provide a compact overview of the numerous currently approved treatments and future innovative approaches, including neuroprotective treatments as anti-LINGO-1 monoclonal antibody and cell therapies, for effective and safe management of MS, potentially leading to a cure for this disease.

01 May 2023·Multiple sclerosis (Houndmills, Basingstoke, England)

Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis

Article

Author: Fetco, Dumitru ; Fisher, Elizabeth ; Belachew, Shibeshih ; Elliott, Colm ; Tian, Zhe ; Bradley, Daniel P ; Zhu, Bing ; Araujo, David ; Gafson, Arie ; Arnold, Douglas L ; Rudko, David A ; Elkady, Ahmed M

Background::

Paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) have been posited as markers of chronic active lesions (CALs).

Objective::

To assess the lesion-level concordance of PRLs and SELs in MS and to characterize changes in brain tissue integrity in CALs over time.

Methods::

MRIs were analyzed from a substudy of AFFINITY [NCT03222973], a phase 2 trial of opicinumab in relapsing MS. Assessments included (1) identification of SELs based on longitudinal MRIs over 72 weeks, and identification of PRLs on susceptibility-weighted imaging (SWI) filtered phase images at week 72; (2) evaluation of subject-level correlation of SEL and PRL counts, volumes, and degree of lesion-level overlap between SELs and PRLs; and (3) characterization of tissue integrity over time in overlapping and non-overlapping SELs and PRLs.

Results::

In 41 subjects, 119 chronic PRLs and 267 SELs were detected. Of 119 (39.5%) chronic PRLs, 47 co-localized with a SEL; 46/267 (17.2%) SELs co-localized with a PRL. PRLs co-localized with SELs showed expansion and worsening microstructural damage over time. SELs with and without co-localization with PRLs showed ongoing tissue damage.

Conclusions::

Chronic MS lesions identified as both PRL and SEL were associated with the most severe accumulation of tissue damage.

Trial Registration::

AFFINITY [NCT03222973].

News (Medical) associated with Opicinumab

21 Oct 2020

·www.biospace.com

Biogen to Halt Work on Opicinumab, Steer Focus Toward Parkinson’s Disease

Biogen is planning to cut its Alzheimer’s drug Adu Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS. Photo courtesy of Biogen. Biogen reported its Q3 2020 financial results today, highlighting that its total revenues had reached $3.3 million. However, this was a 6% decrease from the third quarter of 2019, and the company stated that it would be halting work on opicinumab, its experimental multiple sclerosis (MS) drug. Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS. “As part of our long-standing commitment to the MS community, Biogen remains dedicated to advancing the treatment of MS and continues to pursue next-generation research to understand the therapeutic potential of repairing damage caused by the disease,” said Michael Ehlers, executive vice president, Research & Development at Biogen, at the time of the study’s initiation. However, further analysis and testing suggested that receiving opicinumab did not lead to a reduction in disability. This data was published in The Lancent Neurology back in 2019. Upon disclosing its financial results for the third quarter of 2020, Biogen suggested that it was looking forward to its new collaboration with Denali Therapeutics, which focuses on Parkinson’s disease. “We have continued to allocate capital to create the opportunity for long-term shareholder value, including business development with our new collaboration in Parkinson’s disease,” said Michel Vounatsos, Biogen’s chief executive officer. Denali Therapeutics announced the signing of the LRRK2 Collaboration and License Agreement and a Right of First Negotiation, Option and License Agreement with Biogen on Oct. 7. Under the terms of the collaboration, Denali will receive a $560 million upfront payment. Mutations in LLRK2, or leucine-rich repeat kinase 2, are thought to cause Parkinson’s disease. Researchers are now looking into whether Denali’s small molecule inhibitor of LRRK2, DNL151, can potentially help patients by slowing disease progression. It has been selected to progress into late-stage studies, set to commence in 2021. “Safety and biomarker data from studies of our two LRRK2 molecules in Parkinson’s patients support moving DNL151 into late stage clinical studies with the aim of addressing the devastating clinical decline and pathology of disease in Parkinson’s patients,” said Carole Ho, M.D., Chief Medical Officer. “Our collaboration partner Biogen is a respected leader in neurodegenerative diseases and brings deep scientific and development expertise in Parkinson’s disease which will allow us to accelerate our development plan and we believe increase the likelihood of ultimate success.” A total of 162 healthy volunteers have already received DNL151 as a part of an ongoing Phase I clinical study. In addition, 25 Parkinson’s disease patients have also been given DNL151 in a Phase 1b clinical study. Denali is working on completing further dose escalation cohorts in an expanded Phase I study. Both Biogen and Denali are working to finalize clinical development plans for the product. This is just one of many collaborations that Biogen has entered as of late. On Oct. 6, the company announced that it had also agreed to a research collaboration with Scribe Therapeutics Inc. to develop and commercialize CRISPR-based therapies, with a focus on Amyotrophic Lateral Sclerosis (ALS). “Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics, at the time of the announcement. “We’re proud to collaborate with Biogen and apply our uniquely customized approaches with the goal of developing new, safe and effective genetic medicines for neurodegenerative disease.”

Phase 1Phase 2License out/inFinancial Statement

02 Feb 2017

·www.biospace.com

Why This Big Biotech Could be Biogen’s Downfall

February 2, 2017 By Alex Keown , BioSpace.com Breaking News Staff SUMMIT, N.J. – Could Celgene ’s experimental multiple sclerosis drug ozanimod take a bite out of Biogen ’s share of the market? Ozanimod is a selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, as well as inflammatory bowel disease. In October, Celgene announced positive results from a two-year Phase II trial of ozanimod. The trial showed the oral drug met its primary efficacy endpoint of reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions. Trial data showed that patients were still experiencing benefits even after 96 weeks. What might be most important, as Todd Campbell pointed out in The Motley Fool, there were not any safety concerns with patients taking ozanimod.Celgene acquired ozanimod in 2015 when it bought Receptos for $7.2 billion. If the drug continues through Phase III development, that could be a positive sign for the drug’s marketability, especially since Biogen’s Tecfidera, the dominant oral MS drug, has shown some safety issues concerning a rare and life-threatening brain disease called progressive multifocal leukoencephalopathy, Campbell said. That safety concern could make more doctors willing to prescribe ozanimod, he said. Not only could ozanimod directly challenge Biogen’s hold on the market, but it will also take on rivals Novartis and Sanofi and their drugs, Gilenya and Aubagio, respectively. Tecfidera and Gilenya generated more than $3 billion last year for their companies and Aubagio brought in about $2 billion, Campbell said. In addition to Tecfidera, Biogen also has the recently-approved injectable Zinbryta for treatment of the relapsing form of MS. However, that drug, co-developed with AbbVie , comes with a boxed warning, the most serious warning label provided by the regulatory agency. The FDA recommends the drug be prescribed to patients who have had an “inadequate response to two or more MS drugs” due to safety concerns. Multiple sclerosis is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. MS affects more than 2.3 million people worldwide. Relapsing MS is the most common form of the disease, accounting for 85 percent of cases. Biogen has had a few setbacks in developing MS treatments. Last year, Biogen’s opicinumab (anti-LINGO-1), failed to reach endpoints in its Phase II trial which caused company stock to plunge, and Biogen lost $8 billion in market value in one day. Fox Business reported that Biogen also abandoned future development of MT-1303 , an experimental S1P receptor antagonist product for MS. Although Campbell is high on ozanimod’s potential, he said investors should always remember that approximately 40 percent of Phase III drugs fail.

Phase 2Clinical ResultAcquisitionPhase 3Drug Approval

09 Sep 2016

·www.biospace.com

Advice for Biogen: Take a Page Out of Biotech’s Best Friend Celgene’s Playbook

September 9, 2016 By Alex Keown , BioSpace.com Breaking News Staff BOSTON – While there are countless questions as to whether Biogen will acquire or be acquired, analysts with Citigroup contend that Biogen should look to New Jersey and take a page out of rival drugmaker Celgene ’s playbook— spend money to develop partnerships that will generate new streams of revenue. In a new blog on Barrons, Citigroup ’s Robyn Karnauskas and Mohit Bansal provide their two-cents on how the Boston-based Biogen can grow through striking deals with other companies, much the way Celgene has. It was something the duo put to Paul Clancy , Biogen’s chief financial officer during a recent meeting. While Clancy said striking deals could be beneficial for Biogen, he said the company was committed to the neuro market and did not see a lot pf M&A targets that currently made sense for the company’s long-range goals. Since 2014 Celgene has spent more than $3 billion in partnerships, most noticeably the $1 billion the company invested in a 10-year partnership with Juno Therapeutics or the more recent deal with Jounce Therapeutics that could be worth up to $2.5 billion. Celgene also has collaborations with companies like Agios , Bluebird Bio , Epizyme and others. In 2014, Celgene entered into 10 deals, shelling out an average of $222 million in upfront payments to its partners. Celgene’s partnership goals has been a strategic effort to diversify revenue streams so it is not so financially dependent on its blockbuster blood cancer drug, Revlimid . While the Citigroup analysts suggested Biogen look to form partnerships, there have been questions as to whether or not another company should swoop in and acquire Biogen. Biogen’s revenues are primarily driven by its products treating multiple sclerosis and hemophilia. During Biogen’s most recent quarterly report, its MS leader, Tecfidera, brought in $987 million in the quarter, an increase over the first quarter’s $946 million. Its two hemophilia medications, Electate and Alprolix, brought in $125 million and $80 million, respectively. During the second quarter Biogen reported revenue of $2.9 billion. In a recent article highlighted on BioSpace , the Motley Fool’s George Budwell noted that Biogen is projected to see continued growth, but he pointed out that its focus on the market for central nervous system treatments is a high-risk undertaking. One such drug that could be a financial boondoggle if it fails is the company’s Alzheimer’s treatment, aducanumab, which targets amyloid plaque. If it proves successful though, the risk would likely be well worth the reward as the drug would be a potential blockbuster. But the risk is there. In June, Biogen saw an MS drug, opicinumab, fail in a Phase II trial, which caused the company to lose $8 billion in market value overnight. If the company is a target for takeover, Clancy told the Citigroup analysts the employees working for Biogen, particularly the scientists, may not like the idea of working for another company. He said they would be “less inclined to be a part of a new place with less autonomy,” according to the Barrons’ blog. Biogen is not he first company that has been pointed to Celgene as an example of how to grow through partnerships. In July, analysts at the Motley Fool made a similar recommendation to Foster City, Calif.-based Gilead Sciences . Gilead is known for having a dominant position in the HCV market, with the bulk of the company’s revenue tied up in two drugs, Harvoni and Sovaldi . Those two drugs accounted for $20 billion in revenue in 2015, but, the success of the drugs means there’s a dwindling patient pool in the HCV market.

Phase 2Clinical Trial FailureLicense out/in

100 Deals associated with Opicinumab

External Link

KEGG	Wiki	ATC	Drug Bank
D11767	Opicinumab	-	DB14959

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 2	United States	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Canada	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Czechia	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	France	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Hungary	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Italy	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Netherlands	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Poland	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Russia	Biogen, Inc.	01 Aug 2013
Multiple sclerosis relapse	Phase 2	Serbia	Biogen, Inc.	01 Aug 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03222973 (AFFINITY, CTgov)	Phase 2	Multiple sclerosis relapse	263	placebo (Part 1: Placebo)	dbcivjxvqu(zsxkbzypra) = ovxyrakauc piyhrwaysc (boojrytcrw, bwmgwpufgi - jsgvrwsyjt) View more	-	28 Apr 2022
				BIIB033 (Part 1: BIIB033 750 mg)	dbcivjxvqu(zsxkbzypra) = ngfxfhvxph piyhrwaysc (boojrytcrw, zhykwdobnd - wwrspwcbqp) View more
NCT01721161 (RENEW, ECTRIMS2020)	Phase 2	-	82	Opicinumab 100 mg/kg	okspetnlwj(hascfjtfog) = xxpdgggobt dyktifcldf (cdufoknxeb )	Positive	07 Dec 2020
				Placebo	okspetnlwj(hascfjtfog) = woufnesdvy dyktifcldf (cdufoknxeb )
NCT01721161 (RENEW, AAN2020)	Phase 2	Optic Neuritis	82	Opicinumab	wecpkjbxwz(sszygaobrn) = cdwkidgvem twmoyehwpq (cxefghfjqh )	-	14 Apr 2020
				Placebo	wecpkjbxwz(sszygaobrn) = deepomponv twmoyehwpq (cxefghfjqh )
NCT02657915 (RENEWED, CTgov)	Phase 2	Optic Neuritis	52	Placebo	bvoedhykld(majuhmmwpw) = ulqkayqviu vuaabhideu (bnzsludufr, 4.854) View more	-	23 Sep 2019
NCT01864148 (SYNERGY, AAN2018)	Phase 2	Multiple sclerosis relapse	-	Opicinumab 10 mg/kg	akgyhczfis(yoxxcfbwdl) = iwvvssbyru ulnjcoaddg (xsomcbbkhf )	-	10 Apr 2018
				Placebo (IM IFN beta-1a only)	akgyhczfis(yoxxcfbwdl) = qxngkqzpdx ulnjcoaddg (xsomcbbkhf )
NCT01864148 (SYNERGY, CTgov)	Phase 2	Multiple sclerosis relapse	419	Placebo+Avonex (Placebo)	tlutucbwep = iwceeifnqp icrcdmurfj (ferxxqsayr, zwfhizdyvp - mqlkpqcqtd) View more	-	03 May 2017
				BIIB033+AVONEX (BIIB033, 3 mg/kg)	tlutucbwep = urmpeyhvsw icrcdmurfj (ferxxqsayr, lwwsvrdgln - akmilqhwvv) View more
NCT01721161 (RENEW, CTgov)	Phase 2	Optic Neuritis	82	Placebo (Placebo)	stuascksgv(yowwrhzhwl) = dwndonpeex saoimpnkmc (dszvpuueic, 2.53) View more	-	30 Jun 2016
				BIIB033 (anti-LINGO-1 mAb) (BIIB033)	stuascksgv(yowwrhzhwl) = nsvivtfcez saoimpnkmc (dszvpuueic, 2.53) View more
NCT01721161 (RENEW, AAN2016)	Phase 2	Optic Neuritis	82	Anti-LINGO-1 IV 100 mg/kg	yzkuiknzfy(kcsataoovf) = hmxgvbktez dxruxqtfps (yjzfjseajd )	Positive	05 Apr 2016
				Placebo	yzkuiknzfy(kcsataoovf) = knsyjswgrh dxruxqtfps (yjzfjseajd )
NCT01721161 (RENEW, AAN2016)	Phase 2	Optic Neuritis	82	Anti-LINGO-1 IV	ujtkoxdvar(dkxyiddviu) = hquvugnvtq mcpisayiml (qpsbwzthlz )	-	05 Apr 2016
				Placebo	ujtkoxdvar(dkxyiddviu) = upcrfovvbr mcpisayiml (qpsbwzthlz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis